Do analysts prefer GNS or DPH?

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Given Genus' stronger consensus rating and higher possible upside, research analysts plainly believe Genus is more favorable than Dechra Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Dechra Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation and earnings, HWDN or GNS?

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Howden Joinery Group £2.42B 1.80 £253.42M £49.00 16.11 Genus £672M 2.00 £7.87M £71.00 28.51

Does the media prefer HWDN or GNS?

In the previous week, Howden Joinery Group had 4 more articles in the media than Genus. MarketBeat recorded 5 mentions for Howden Joinery Group and 1 mentions for Genus. Howden Joinery Group's average media sentiment score of 0.67 beat Genus' score of 0.00 indicating that Howden Joinery Group is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Howden Joinery Group 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend GNS or CTY?

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than City of London. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 City of London 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better earnings & valuation, GNS or CTY?

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.00 £7.87M £71.00 28.51 City of London £568.96M 5.20 £294.08M £113.99 5.04

Is GNS or CTY more profitable?

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity. Company Net Margins Return on Equity Return on Assets Genus 7.07% 9.70% 3.31% City of London 97.40% 22.92% 4.00%

Does the media prefer GNS or CTY?

In the previous week, City of London had 11 more articles in the media than Genus. MarketBeat recorded 12 mentions for City of London and 1 mentions for Genus. City of London's average media sentiment score of 0.50 beat Genus' score of 0.00 indicating that City of London is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral City of London 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, SMWH or GNS?

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio WH Smith £1.59B 0.39 £63.01M -£96.70 N/A Genus £672M 2.00 £7.87M £71.00 28.51

Is SMWH or GNS more profitable?

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity. Company Net Margins Return on Equity Return on Assets WH Smith -9.48% -90.46% 6.62% Genus 7.07% 9.70% 3.31%

Does the media refer more to SMWH or GNS?

In the previous week, WH Smith and WH Smith both had 1 articles in the media. WH Smith's average media sentiment score of 0.75 beat Genus' score of 0.00 indicating that WH Smith is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment WH Smith 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Genus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, GNS or CPG?

Compass Group has higher revenue and earnings than Genus. Compass Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genus £672M 2.00 £7.87M £71.00 28.51 Compass Group £48.49B 0.01 £1.35B £118.70 0.27

Does the media refer more to GNS or CPG?

In the previous week, Genus and Genus both had 1 articles in the media. Genus' average media sentiment score of 0.00 equaled Compass Group'saverage media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genus 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Compass Group 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Genus (GNS) Competitors

GBX 2,024.33 +4.33 (+0.21%)

As of 12:20 PM Eastern

Compare

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

Should you buy Genus stock or one of its competitors? MarketBeat compares Genus with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Genus include Dechra Pharmaceuticals (DPH), Howden Joinery Group (HWDN), City of London (CTY), WH Smith (SMWH), and Compass Group (CPG). These companies are all part of the "personal services" industry.

How does Genus compare to Dechra Pharmaceuticals?

Genus (LON:GNS) and Dechra Pharmaceuticals (LON:DPH) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, media sentiment, risk, valuation, earnings and dividends.

52.2% of Genus shares are owned by institutional investors. Comparatively, 105.5% of Dechra Pharmaceuticals shares are owned by institutional investors. 0.7% of Genus shares are owned by company insiders. Comparatively, 9.3% of Dechra Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Genus has higher earnings, but lower revenue than Dechra Pharmaceuticals. Dechra Pharmaceuticals is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.00	£7.87M	£71.00	28.51
Dechra Pharmaceuticals	£761.50M	0.00	-£27.90M	-£0.25	N/A

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Given Genus' stronger consensus rating and higher possible upside, research analysts plainly believe Genus is more favorable than Dechra Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Dechra Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Genus has a net margin of 7.07% compared to Dechra Pharmaceuticals' net margin of -3.66%. Genus' return on equity of 9.70% beat Dechra Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Dechra Pharmaceuticals	-3.66%	-3.92%	0.75%

In the previous week, Genus had 1 more articles in the media than Dechra Pharmaceuticals. MarketBeat recorded 1 mentions for Genus and 0 mentions for Dechra Pharmaceuticals. Genus' average media sentiment score of 0.00 equaled Dechra Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
Genus	Neutral
Dechra Pharmaceuticals	Neutral

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.6%. Dechra Pharmaceuticals pays an annual dividend of GBX 45 per share. Genus pays out 45.1% of its earnings in the form of a dividend. Dechra Pharmaceuticals pays out -18,000.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, Dechra Pharmaceuticals has a beta of 0.78, suggesting that its stock price is 22% less volatile than the broader market.

Summary

Genus beats Dechra Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Genus compare to Howden Joinery Group?

Howden Joinery Group (LON:HWDN) and Genus (LON:GNS) are both personal services companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, earnings, profitability, media sentiment, analyst recommendations and risk.

Howden Joinery Group pays an annual dividend of GBX 21.30 per share and has a dividend yield of 2.7%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.6%. Howden Joinery Group pays out 43.5% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Howden Joinery Group is clearly the better dividend stock, given its higher yield and lower payout ratio.

67.4% of Howden Joinery Group shares are held by institutional investors. Comparatively, 52.2% of Genus shares are held by institutional investors. 1.0% of Howden Joinery Group shares are held by company insiders. Comparatively, 0.7% of Genus shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Howden Joinery Group has a beta of 1.302, meaning that its stock price is 30% more volatile than the broader market. Comparatively, Genus has a beta of 0.901, meaning that its stock price is 10% less volatile than the broader market.

Howden Joinery Group presently has a consensus price target of GBX 993.17, indicating a potential upside of 25.81%. Genus has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Given Genus' stronger consensus rating and higher probable upside, analysts clearly believe Genus is more favorable than Howden Joinery Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Howden Joinery Group	0 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Howden Joinery Group has a net margin of 11.07% compared to Genus' net margin of 7.07%. Howden Joinery Group's return on equity of 23.58% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Howden Joinery Group	11.07%	23.58%	10.70%
Genus	7.07%	9.70%	3.31%

In the previous week, Howden Joinery Group had 4 more articles in the media than Genus. MarketBeat recorded 5 mentions for Howden Joinery Group and 1 mentions for Genus. Howden Joinery Group's average media sentiment score of 0.67 beat Genus' score of 0.00 indicating that Howden Joinery Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Howden Joinery Group	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Howden Joinery Group has higher revenue and earnings than Genus. Howden Joinery Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Howden Joinery Group	£2.42B	1.80	£253.42M	£49.00	16.11
Genus	£672M	2.00	£7.87M	£71.00	28.51

Summary

Howden Joinery Group beats Genus on 12 of the 18 factors compared between the two stocks.

How does Genus compare to City of London?

Genus (LON:GNS) and City of London (LON:CTY) are both personal services companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and valuation.

Genus has a beta of 0.901, indicating that its stock price is 10% less volatile than the broader market. Comparatively, City of London has a beta of 0.8605065, indicating that its stock price is 14% less volatile than the broader market.

52.2% of Genus shares are held by institutional investors. Comparatively, 8.7% of City of London shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 0.1% of City of London shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

City of London has a net margin of 97.40% compared to Genus' net margin of 7.07%. City of London's return on equity of 22.92% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
City of London	97.40%	22.92%	4.00%

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.6%. City of London pays an annual dividend of GBX 21.45 per share and has a dividend yield of 3.7%. Genus pays out 45.1% of its earnings in the form of a dividend. City of London pays out 18.8% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. City of London is clearly the better dividend stock, given its higher yield and lower payout ratio.

Genus currently has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Given Genus' stronger consensus rating and higher probable upside, research analysts clearly believe Genus is more favorable than City of London.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
City of London	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, City of London had 11 more articles in the media than Genus. MarketBeat recorded 12 mentions for City of London and 1 mentions for Genus. City of London's average media sentiment score of 0.50 beat Genus' score of 0.00 indicating that City of London is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
City of London	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

City of London has lower revenue, but higher earnings than Genus. City of London is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.00	£7.87M	£71.00	28.51
City of London	£568.96M	5.20	£294.08M	£113.99	5.04

Summary

City of London beats Genus on 10 of the 18 factors compared between the two stocks.

How does Genus compare to WH Smith?

WH Smith (LON:SMWH) and Genus (LON:GNS) are both small-cap personal services companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings.

WH Smith pays an annual dividend of GBX 17.30 per share and has a dividend yield of 4.2%. Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.6%. WH Smith pays out -17.9% of its earnings in the form of a dividend. Genus pays out 45.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. WH Smith is clearly the better dividend stock, given its higher yield and lower payout ratio.

WH Smith has a beta of 0.922, suggesting that its stock price is 8% less volatile than the broader market. Comparatively, Genus has a beta of 0.901, suggesting that its stock price is 10% less volatile than the broader market.

Genus has a net margin of 7.07% compared to WH Smith's net margin of -9.48%. Genus' return on equity of 9.70% beat WH Smith's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
WH Smith	-9.48%	-90.46%	6.62%
Genus	7.07%	9.70%	3.31%

In the previous week, WH Smith and WH Smith both had 1 articles in the media. WH Smith's average media sentiment score of 0.75 beat Genus' score of 0.00 indicating that WH Smith is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
WH Smith	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Genus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

WH Smith presently has a consensus target price of GBX 570, suggesting a potential upside of 39.31%. Genus has a consensus target price of GBX 3,216.67, suggesting a potential upside of 58.90%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than WH Smith.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
WH Smith	0 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.43
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

71.9% of WH Smith shares are held by institutional investors. Comparatively, 52.2% of Genus shares are held by institutional investors. 0.9% of WH Smith shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

WH Smith has higher revenue and earnings than Genus. WH Smith is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
WH Smith	£1.59B	0.39	£63.01M	-£96.70	N/A
Genus	£672M	2.00	£7.87M	£71.00	28.51

Summary

WH Smith beats Genus on 9 of the 16 factors compared between the two stocks.

How does Genus compare to Compass Group?

Genus (LON:GNS) and Compass Group (LON:CPG) are both small-cap personal services companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations.

Genus has a beta of 0.901, indicating that its stock price is 10% less volatile than the broader market. Comparatively, Compass Group has a beta of 0.654, indicating that its stock price is 35% less volatile than the broader market.

In the previous week, Genus and Genus both had 1 articles in the media. Genus' average media sentiment score of 0.00 equaled Compass Group'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Compass Group	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genus has a net margin of 7.07% compared to Compass Group's net margin of 4.20%. Compass Group's return on equity of 26.12% beat Genus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Compass Group	4.20%	26.12%	7.52%

Compass Group has higher revenue and earnings than Genus. Compass Group is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.00	£7.87M	£71.00	28.51
Compass Group	£48.49B	0.01	£1.35B	£118.70	0.27

Genus pays an annual dividend of GBX 32 per share and has a dividend yield of 1.6%. Compass Group pays an annual dividend of GBX 66.38 per share and has a dividend yield of 205.6%. Genus pays out 45.1% of its earnings in the form of a dividend. Compass Group pays out 55.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Genus presently has a consensus price target of GBX 3,216.67, indicating a potential upside of 58.90%. Compass Group has a consensus price target of GBX 2,932.50, indicating a potential upside of 8,984.57%. Given Compass Group's higher possible upside, analysts plainly believe Compass Group is more favorable than Genus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Compass Group	0 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	3.00

52.2% of Genus shares are held by institutional investors. Comparatively, 68.2% of Compass Group shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 0.5% of Compass Group shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Compass Group beats Genus on 9 of the 15 factors compared between the two stocks.

Get Genus News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GNS vs. The Competition

Export

Metric	Genus	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	£1.34B	£517.58M	£7.06B	£2.78B
Dividend Yield	1.59%	3.90%	2.68%	6.17%
P/E Ratio	28.51	3.47	22.37	368.18
Price / Sales	2.00	6,436.17	526.89	84,613.91
Price / Cash	50.56	13.13	29.22	27.87
Price / Book	2.44	85.93	10.75	7.49
Net Income	£7.87M	-£96.07M	£3.58B	£5.89B
7 Day Performance	-9.95%	-1.18%	-2.10%	-0.48%
1 Month Performance	-7.23%	2.45%	3.32%	-1.00%
1 Year Performance	-8.81%	60.93%	28.17%	61.74%

Genus Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GNS Genus	2.7502 of 5 stars	GBX 2,024.33 +0.2%	GBX 3,216.67 +58.9%	-9.0%	£1.34B	£672M	28.51	480	Gap Down
DPH Dechra Pharmaceuticals	N/A	N/A	N/A	N/A	£4.40B	£761.50M	N/A	2,457
HWDN Howden Joinery Group	4.3206 of 5 stars	GBX 774 -4.0%	GBX 993.17 +28.3%	-6.3%	£4.26B	£2.42B	15.80	12,000	News Coverage Positive News
CTY City of London	N/A	GBX 571 -1.7%	N/A	+16.5%	£2.94B	£568.96M	5.01	N/A	News Coverage Positive News
SMWH WH Smith	4.0594 of 5 stars	GBX 394.60 -4.8%	GBX 570 +44.5%	-61.3%	£593.87M	£1.59B	N/A	14,935	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:GNS) was last updated on 7/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Genus (GNS) Competitors

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

How does Genus compare to Dechra Pharmaceuticals?

Summary

How does Genus compare to Howden Joinery Group?

Summary

How does Genus compare to City of London?

Summary

How does Genus compare to WH Smith?

Summary

How does Genus compare to Compass Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Genus (GNS) Competitors

GNS vs. DPH, HWDN, CTY, SMWH, and CPG

How does Genus compare to Dechra Pharmaceuticals?

Do insiders and institutionals hold more shares of GNS or DPH?

Which has better earnings and valuation, GNS or DPH?

Do analysts prefer GNS or DPH?

Is GNS or DPH more profitable?

Does the media prefer GNS or DPH?

Is GNS or DPH a better dividend stock?

Which has more risk and volatility, GNS or DPH?

Summary

How does Genus compare to Howden Joinery Group?

Is HWDN or GNS a better dividend stock?

Do insiders & institutionals believe in HWDN or GNS?

Which has more volatility and risk, HWDN or GNS?

Do analysts prefer HWDN or GNS?

Is HWDN or GNS more profitable?

Does the media prefer HWDN or GNS?

Which has higher valuation and earnings, HWDN or GNS?

Summary

How does Genus compare to City of London?

Which has more volatility & risk, GNS or CTY?

Do institutionals and insiders hold more shares of GNS or CTY?

Is GNS or CTY more profitable?

Is GNS or CTY a better dividend stock?

Do analysts recommend GNS or CTY?

Does the media prefer GNS or CTY?

Which has better earnings & valuation, GNS or CTY?

Summary

How does Genus compare to WH Smith?

Is SMWH or GNS a better dividend stock?

Which has more risk and volatility, SMWH or GNS?

Is SMWH or GNS more profitable?

Does the media refer more to SMWH or GNS?

Do analysts prefer SMWH or GNS?

Do insiders & institutionals believe in SMWH or GNS?

Which has stronger earnings and valuation, SMWH or GNS?

Summary

How does Genus compare to Compass Group?

Which has more volatility & risk, GNS or CPG?

Does the media refer more to GNS or CPG?

Is GNS or CPG more profitable?

Which has higher valuation and earnings, GNS or CPG?

Is GNS or CPG a better dividend stock?

Do analysts prefer GNS or CPG?

Do insiders & institutionals have more ownership in GNS or CPG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNS vs. The Competition

Genus Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools